News
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
Dr. Einav Nili Gal-Yam, head of the Breast Oncology Institute at Chaim Sheba Medical Center, was...
Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms
Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration...
Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was...
Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic...
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Sermonix used the Tempus TIME Trial® Network to enroll 45% of its ELAINE-2 patients The company is...
Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
To sign up for future Sermonix press releases, please enter your information below.